SPOTLIGHT: Cardiome delays analysis


There's plenty of buzz this morning about Cardiome Pharma, which announced that it is delaying an interim analysis on a key heart drug--vernakalant--so it can add data from more patients in the Phase IIb study. Analysts say the company is likely involved in partnership talks. Cardiome now expects to release the analysis in March. Release